Fair value measurement (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis

The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017:

	Total carrying value at September 30, 2018		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
	(Dollars in thousands)
Investments in marketable securities	$	9,849	$	9,849	$	—	$	—
Derivative assets	2,333		—		2,333		—
Derivative liabilities	1,636		—		1,636		—
Contingent consideration liabilities	244,574		—		—		244,574

	Total carrying value at December 31, 2017		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
	(Dollars in thousands)
Investments in marketable securities	$	9,045	$	9,045	$	—	$	—
Derivative assets	1,221		—		1,221		—
Derivative liabilities	1,426		—		1,426		—
Contingent consideration liabilities	272,136		—		—		272,136

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition.

	Valuation Technique	Unobservable Input	Range
Contingent consideration	Monte Carlo simulation	Revenue volatility	24.1	%
		Risk free rate	Cost of debt structure
		Projected year of payment	2019 - 2021

Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis

The following table provides information regarding changes, during the nine months ended September 30, 2018, in Level 3 financial liabilities related to contingent consideration:

	Contingent consideration
	2018
	(Dollars in thousands)
Balance - December 31, 2017	$	272,136
Additions (1)	396
Payments (2)	(75,252		)
Revaluations	47,344
Translation adjustment	(50		)
Balance - September 30, 2018	$	244,574

(1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular.

(2) Consists mainly of a $75.0 million payment resulting from the achievement of a sales goal associated with the NeoTract acquisition for the period from January 1, 2018 to April 30, 2018.